: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Fri, 06 Nov 2009 17:26:18 GMT

Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.[More...]

Bulls Back On Track?

Fri, 06 Nov 2009 16:21:18 GMT

Good morning. With chants of "Dow 10K… Dow 10K" once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.[More...]

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Fri, 06 Nov 2009 13:52:50 GMT

Ford's 2,215 page 2007 master contract with the UAW 1941 UAW-Ford contract[More...]

Your Kind of Day?

Thu, 05 Nov 2009 19:06:48 GMT

As a rule, I try not to read too terribly much into a "Fed Day" as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on "Fed Days." But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.[More...]

The Dollar-Proof Portfolio

Thu, 05 Nov 2009 17:31:14 GMT

Don't put off this important piece of the financial-planning process.[More...]

Celgene: Buy On A Pullback

Wed, 04 Nov 2009 17:04:19 GMT

“So why do we like Celgene so much, and how come we have time? The main reason I like it is its huge blood cancer drug Revlimid. $1.3 billion sales in 2008. It’s approved by the FDA to treat multiple myeloma. That’s a cancer of the plasma cells and bone marrow. These cancers are horrible…[More...]

What Investors Should Look for In Today’s Fed Statement

Wed, 04 Nov 2009 13:04:24 GMT

In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).[More...]

Are Discount Brokers Shares Worth Owning?

Wed, 04 Nov 2009 01:28:03 GMT

The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&P gain 15%.[More...]

Technology Rises And Buying Facebook

Tue, 03 Nov 2009 16:54:11 GMT

Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%. Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.[More...]

Buffett Gets His Cheque Book Out

Tue, 03 Nov 2009 16:17:34 GMT

Given the slew of positive economic data Monday you might have been forgiven for expecting a decent rebound in risk assets. There was a rebound of sorts in early New York trading, with the Dow up close to 150 points at one stage.[More...]

Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years

Fri, 06 Nov 2009 11:46:00 GMT

Nov. 6--Targacept Inc. posted its first quarterly profit in nearly three years yesterday, bolstered in large part by a $10 million milestone payment by AstraZeneca PLC.
Targacept, based in Piedmont Triad Research Park in Winston-Salem, is developing drugs based on nicotine research to treat diseases of the central nervous system.
The payment was the result of Targacept's research in adult attention deficit/hyperactivity disorder involving its AZD3480 drug compound, also known as TC-1734.

: iStockAnalyst.com Symbols Feed

Biostar Raises $3.6 Million

Bulls Back On Track?

Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules

Your Kind of Day?

The Dollar-Proof Portfolio

Celgene: Buy On A Pullback

What Investors Should Look for In Today’s Fed Statement

Are Discount Brokers Shares Worth Owning?

Technology Rises And Buying Facebook

Buffett Gets His Cheque Book Out

Targacept has profit in quarter: Large milestone payment by AstraZeneca credited for first profit in almost three years

Auditor: Canada disaster planning is poor

Vaccine-short Canada exporting 'surplus'

Largest malaria vaccine trial under way

Canada's H1N1 flu vaccine running short

GlaxoSmithKline third quarter profit up 11 percent

FDA OK's new leukemia treatment

Evening Standard, London, Market Report Column

Earnings Preview: Bristol-Myers 3Q earnings report

FDA OK's pediatric seasonal flu vaccine

MethylGene Reports Third Quarter 2009 Financial Results

Procter &Amp; Gamble Co. Up 13% Since Added to Galtstock Long Portfolio

Celgene Reports Record Third Quarter 2009 Operating and Financial Results

Pronova BioPharma Receives 2009 Frost &Amp; Sullivan Award for Excellence in Financial &Amp; Risk Management

Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma

85% Profitable Trades Keep Galtstock.Com Subscribers Very Happy

Tennis Legend John McEnroe Tells Men to 'Get Serious' About Prostate Cancer

Lawsuit Claims Celgene Corporation Misappropriated the Idea Behind its Multiple Myeloma Treatments

GSK Advisory: Warehouse Theft

Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy

Form 4 Heller Frances K For: Nov 02 (10K)

Form 4 CELGENE CORP /DE/ For: Oct 27 Filed by: Burton Graham (10K)

Form 4 GRYSKA DAVID W For: Oct 13 (10K)

Form 4 Burton Graham For: Oct 13 (10K)

Form 4 BARER SOL J For: Oct 13 (10K)

Form 4 HUGIN ROBERT J For: Oct 13 (10K)

Form 4 Van Hoek Andre For: Oct 13 (10K)

Form 4 PONIARD PHARMACEUTICALS, For: Oct 06 Filed by: MARTELL RON (10K)

Form 4 HUGIN ROBERT J For: Oct 05 (10K)

Form 4 Van Hoek Andre For: Oct 01 (10K)